Published 2 months ago • loading... • Updated 2 months ago

Noninvasive brain treatment for depression proves helpful

Today, a randomized trial at Stanford's Brain Stimulation Lab found half of 24 participants achieved remission at one month, versus nearly 21% in the placebo group, the study published in World Psychiatry shows.
SAINT was developed to target the strongest connection between the left dorsolateral prefrontal cortex and subgenual cingulate using structural and functional MRI, delivering thousands of rapid magnetic pulses across ten 10-minute sessions per day for five consecutive days.
Biological markers in the trial revealed Electroencephalograms showed SAINT affected beta brain waves tied to focus, decreased beta power in the left anterior cingulate, and SAINT's second clinical trial reported 90.5% remission in 21 participants.
FDA cleared SAINT in September 2022, and Magnus Medical, SAINT license holder, offers it at 17 clinics in the United States, aiming to double this by the end of 2026.
Study limitations include excluding acutely suicidal patients, a largely White, highly educated study population, and the need for more data on durability of benefit and comparative trials with conventional transcranial magnetic stimulation .

Insights by Ground AI

11 Articles

WXOW

+4 Reposted by 4 other sources

Center

First on Cnn: a New Experimental Therapy Offers Hope for Depression Patients

At 27, Valerie Zeko watched summer slip away from the solitude of her sofa. While others enjoyed the beach, she remained captive in front of the television, unable to connect with friends or her surroundings. What…

2 months ago

Read Full Article